Janus Kinase Inhibitors Market | Key Companies Eli Lilly, Astellas, Pfizer, Baxter International, Novartis, AbbVie, Sierra Oncology, CTI BioPharma, and Incyte
As per the DelveInsight, JAK Inhibitors Pipeline is expected to be fuelled by rising prescription demand, however side effects, safety issues, regulatory clearances, and labeling restrictions are the key concerns hampering their growth. Currently, some of the key companies investing in the JAK Inhibitors Portfolio to advance the market share includes Eli Lilly and Company, Astellas Pharma US, Pf..